fluorobenzenes has been researched along with Ischemia in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 4 (80.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cheng, M; Gao, XM; Goukassian, D; Hu, Y; Kishore, R; Liao, YH; Qin, B; Qin, G; Tang, YL; Wang, H; Wang, Q; Wu, M; Zhao, TC; Zhou, J; Zhu, Y | 1 |
| Gori, T; Liuni, A; Luca, MC; Parker, JD | 2 |
| de Rooij, M; Meijer, P; Rongen, GA; Scheffer, GJ; Smits, P; van den Broek, PH; Wouters, CW | 1 |
| Bassetti, CL; Hermann, DM; Kilic, E; Kilic, U; Lüscher, TF; Matter, CM | 1 |
2 trial(s) available for fluorobenzenes and Ischemia
| Article | Year |
|---|---|
Upregulation of ecto-5'-nucleotidase by rosuvastatin increases the vasodilator response to ischemia.
Topics: 5'-Nucleotidase; Adenosine; Blood Flow Velocity; Brachial Artery; Caffeine; Central Nervous System Stimulants; Female; Fluorobenzenes; Forearm; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Infusions, Intra-Arterial; Ischemia; Male; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Time Factors; Up-Regulation; Vasodilator Agents; Young Adult | 2010 |
Loss of the preconditioning effect of rosuvastatin during sustained therapy: a human in vivo study.
Topics: Adolescent; Adult; Analysis of Variance; Blood Flow Velocity; Celecoxib; Cyclooxygenase 2 Inhibitors; Double-Blind Method; Drug Administration Schedule; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperemia; Ischemia; Male; Ontario; Pyrazoles; Pyrimidines; Radial Artery; Regional Blood Flow; Reperfusion Injury; Rosuvastatin Calcium; Sulfonamides; Time Factors; Vasodilation; Young Adult | 2012 |
3 other study(ies) available for fluorobenzenes and Ischemia
| Article | Year |
|---|---|
Rosuvastatin enhances angiogenesis via eNOS-dependent mobilization of endothelial progenitor cells.
Topics: Animals; Bone Marrow; Cell Differentiation; Cell Lineage; Cell Movement; Endothelial Cells; Fluorobenzenes; Hindlimb; Ischemia; Male; Mice; Mice, Inbred C57BL; Neovascularization, Physiologic; Nitric Oxide Synthase Type III; Pyrimidines; Regional Blood Flow; Rosuvastatin Calcium; Stem Cells; Sulfonamides | 2013 |
The endothelial-protective effects of HMG-CoA reductase inhibition in the setting of ischemia and reperfusion injury.
Topics: Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Endothelium, Vascular; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ischemia; Protective Agents; Pyrimidines; Reperfusion Injury; Rosuvastatin Calcium; Sulfonamides | 2010 |
Aggravation of focal cerebral ischemia by tissue plasminogen activator is reversed by 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor but does not depend on endothelial NO synthase.
Topics: Animals; Blotting, Western; Brain; Brain Ischemia; Enzyme Inhibitors; Fluorobenzenes; Gene Expression Regulation, Enzymologic; Hydroxymethylglutaryl-CoA-Reductases, NADP-dependent; Ischemia; Laser-Doppler Flowmetry; Male; MAP Kinase Signaling System; Mice; Mice, Inbred C57BL; Mice, Knockout; Mitogen-Activated Protein Kinase 1; Nitric Oxide Synthase Type III; p38 Mitogen-Activated Protein Kinases; Pyrimidines; Rosuvastatin Calcium; Signal Transduction; Stroke; Sulfonamides; Thrombolytic Therapy; Time Factors; Tissue Plasminogen Activator | 2005 |